Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Decitabine Improves Overall Survival in Older AML Patients

TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Conference Correspondent, Conference Correspondent, Hematologic Cancers
Wayne Kuznar

CHICAGO—Decitabine extends overall survival and improves response rates compared with standard therapies in the treatment of older patients with newly diagnosed acute myelogenous leukemia (AML), said Xavier G. Thomas, MD, PhD.

The treatment options for older patients with AML are limited. Intensive chemotherapy is generally poorly tolerated in this group, the initial mortality rate is high (exceeding 30% at 8 weeks), the response rate to chemotherapy is poor, and relapse rates are high. Recently, DNA hypermethylation has been demonstrated in the promoter region in AML. Hypomethylating agents may affect tumor suppression genes and have been shown to be beneficial in AML cell lines, said Thomas, who is with the department of hematology, Edouard-Herriot Hospital, Lyon, France.

Among the hypomethylating agents, decitabine has been approved for patients with myelodysplastic syndrome, and has demonstrated activity in a previous phase 2 trial of patients older than 60 years with AML.

Based on these results, a phase 3 multicenter, controlled, open-label trial was designed to compare decitabine with patients’ choice of treatment on overall survival in patients 65 years and older with newly diagnosed de novo or secondary AML and poor- or intermediaterisk cytogenetics. The 485 patients enrolled were randomized to decitabine, 20 mg/m2 as a 1-hour intravenous infusion once daily for 5 consecutive days, every 4 weeks, or treatment of choice. Patients assigned to treatment of choice could select low-dose cytarabine, 20- mg/m2 subcutaneous injection once daily for 10 days, every 4 weeks (n = 243), or supportive care (n = 28).

Patients assigned to decitabine had a median duration of treatment of 4.4 months compared with 2.4 months for those on the treatment-of-choice arm.

The protocol-specified final analysis (after 396 deaths) showed a nonsignificant but favorable trend for increased overall survival for patients treated with decitabine, with a median survival of 7.7 months compared with 5.0 months in the treatment-of-choice arm (P = .10). Seventy-five patients received disease- modifying therapy after treatment failure following randomization. When these 75 patients were censored from the analysis, median overall survival improved to 8.5 months in the decitabine group and 5.3 months in the treatment-of-choice arm, corresponding to a 20% reduction in the risk of mortality in the decitabine arm, and the difference became statistically significant (P = .044).

An updated unplanned overall analysis was performed with 446 deaths, or approximately an additional year of patient follow-up. This updated analysis showed the same median survival in the 2 groups (7.7 vs 5.0 months) but the effect became significant (nominal P = .037). “This analysis increases the strength and validity of the first clinical cutoff,” said Thomas.

The secondary end point of complete remission with incomplete platelet recovery or complete remission with incomplete blood count recovery was achieved by 17.8% of the decitabine arm compared with 7.8% on treatment of choice.

Adverse event rates were consistent with the known decitabine safety profile and without major differences between the treatment arms.

Related Items
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Pancreatic Cancer
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Last modified: May 21, 2015